Royalty Report: Drugs, Nutraceutical, Food – Collection: 27269


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Nutraceutical
  • Food

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27269

License Grant
The Company acquired from shareholder and former President of the Company of Israel, exclusive rights and interests to a thirteen step process which utilizes virtually the whole of the nutrients found in plants to manufacture herbal dietary supplements.

IPSCIO Record ID: 7635

License Grant
Israelis Licensor hereby grants to Israelis Licensee the exclusive right and license under the Patent Rights to make, have made, use and sell Licensed Products in the Territory, for the Field of Use.
License Property
Licensor is the owner of certain 'Patent Rights' (as defined in Article 1) relating to improved oral delivery of lipophilic substances.
Field of Use
'Field of Use' shall mean the field of Nutraceuticals, specifically in the following categories formulation of food and dietary supplements, food additives, nutritional ingredients, natural ingredients, food industry, food ingredients, food and functional food applications, nutritional beverages, vitamins, minerals, herbals, herbal supplements, health nutrients, phytonutraceuticals, cosmetics, cosmoceuticals (excluding any and all existing or future topical pharmaceutical applications and or uses in the cosmetic and/or cosmoceuticals fields) and any new applications or uses developed or arising in the field of Nutraceuticals.

IPSCIO Record ID: 4735

License Grant
The Licensor was assigned the License agreement related to dietary supplements and drugs, by the original Licensor in a Stock Purchase Agreement.
License Property
Dietary supplements including glucan and fulvic acid and herbal enhanced analgesic formulations.
Field of Use
Licensee is a biotechnology company engaged in the research and development, marketing and sale of lifestyle, dietary supplements and drugs.

IPSCIO Record ID: 26256

License Grant
The Company entered into a license agreement with University that grants the Company an exclusive, worldwide license to (1) the PharmaPrint Process; (2) use certain therapeutic compounds; and (3) other related products developed by Dr. Khwaja's laboratory at USC. USC has also agreed to grant the Company the right to sublicense certain products and a right of first refusal to obtain a license for any improvements to certain products developed by USC. The term of the USC License Agreement began March 1, 1995, and ends on the later of February 28, 2010, or the expiration of the last issued patent under the USC License Agreement.
License Property
PharmaPrint Process technology develops pharmaceutical-grade dietary supplement products and pharmaceuticals from botanical sources. Unlike the traditional drug development process of identifying and synthesizing single bioactive molecules from plant sources, the Company's core technologies were developed based on empirical data that suggests that the health benefits and safe usage of certain plant-derived therapeutics might be the result of the natural combination of multiple molecules found in the plant extract and that single molecules, in isolation, may not replicate the natural plants' effectiveness. The PharmaPrint Process technology enables the Company to identify and quantify the bioactives within plant sources that are believed to provide therapeutic benefits and produce dietary supplements and pharmaceuticals having consistent batch-to-batch quantities and ratios of these bioactives.

IPSCIO Record ID: 5375

License Grant
The University hereby grants to Licensee a semi-exclusive license under the University interest in the University Patent Rights in the Licensed Field to make, have made, use, and sell Licensed Products and to practice Licensed Method.
License Property
Licensed Product (s) means any material or product or kit, or any service, process, or procedure that (1) either is covered by the University Patent Rights or whose manufacture, use, or sale would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of any claim within the University Patent Rights (U.S. Patent Application Numbers 94-0809-1, 95-0315-1 and 95-0413-1) or (2) is discovered, developed, made, sold, registered, or practiced using Licensed Method or which may be used to practice the Licensed Method, in whole or in part.
Field of Use
Certain inventions relating to the development of phytoremediation technology, with application to the field of nutritional and dietary supplements, were made in the course of research sponsored by Licensee.

Licensed Field  means the use for nutritional and dietary supplements.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.